Literature DB >> 14973140

Regulation of alpha1(I) collagen messenger RNA decay by interactions with alphaCP at the 3'-untranslated region.

Jeffrey N Lindquist1, Christopher J Parsons, Branko Stefanovic, David A Brenner.   

Abstract

Liver fibrosis is characterized by an increased deposition of extracellular matrix proteins, including collagen type I, by activated hepatic stellate cells (HSCs). Previous studies have shown that this increase is mediated primarily by a post-transcriptional mechanism. In particular, the RNA-binding protein alphaCP binds to the alpha1(I) collagen 3'-untranslated region (UTR) and stabilizes this RNA in activated, but not quiescent, HSCs. This study examines the role of alphaCP in the decay of transcripts containing the collagen 3'-UTR in extracts obtained from NIH fibroblasts and quiescent and activated HSCs. Using an in vitro decay system, alphaCP binding activity was competed out with the addition of wild type oligonucleotides, but not with mutant oligonucleotides. Competition of alphaCP binding activity increased the rate of decay of wild type transcripts containing the alphaCP 3'-UTR binding site, but not of transcripts containing a mutated binding site. Quiescent HSC extracts contain no alphaCP binding activity and have no difference in the rate of decay of transcripts with wild type and mutant binding sites for alphaCP. The addition of recombinant alphaCP was sufficient to increase the half-life of the wild type transcript, whereas that of the mutant transcript was minimally changed. In vitro decay assays performed with activated HSC extracts that contain alphaCP binding activity demonstrate a markedly reduced decay rate of wild type compared with mutant transcripts. In vivo small interfering RNA experiments targeting alphaCP showed a reduction of the binding activity of alphaCP and a concomitant reduction in intracellular levels of alpha1(I) collagen messenger RNA. In conclusion, this study demonstrates the direct role of alphaCP in the stabilization of alpha1(I) collagen messenger RNA by blocking RNA degradation in activated HSCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973140     DOI: 10.1074/jbc.M314060200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Targeting collagen expression in alcoholic liver disease.

Authors:  Kyle J Thompson; Iain H McKillop; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Enhancement of procollagen biosynthesis by p180 through augmented ribosome association on the endoplasmic reticulum in response to stimulated secretion.

Authors:  Tomonori Ueno; Keisuke Tanaka; Keiko Kaneko; Yuki Taga; Tetsutaro Sata; Shinkichi Irie; Shunji Hattori; Kiyoko Ogawa-Goto
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

3.  RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1.

Authors:  Dillon Fritz; Branko Stefanovic
Journal:  J Mol Biol       Date:  2007-06-09       Impact factor: 5.469

Review 4.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

Review 5.  Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Authors:  Jing-Ting Li; Zhang-Xiu Liao; Jie Ping; Dan Xu; Hui Wang
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

6.  A novel role of vimentin filaments: binding and stabilization of collagen mRNAs.

Authors:  Azariyas A Challa; Branko Stefanovic
Journal:  Mol Cell Biol       Date:  2011-07-11       Impact factor: 4.272

Review 7.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

8.  Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury.

Authors:  Soo Young Park; Hye Won Shin; Kyoung Bun Lee; Min-Jae Lee; Ja-June Jang
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

9.  TGF-beta1 gene silencing for treating liver fibrosis.

Authors:  Kun Cheng; Ningning Yang; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

Review 10.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.